Growth Factor Receptor Targeting

Growth factor receptor targeting employs monoclonal antibodies or small molecules blocking stimulatory signals promoting malignant proliferation. Epidermal growth factor receptor inhibition prevents tumour progression. HER2 targeting improves breast cancer outcomes. VEGF receptor blockade prevents angiogenesis. Resistance mechanisms including pathway activation complicate therapy.

Companion diagnostics identify treatment-responsive populations. Combination therapies enhance single-agent efficacy. Emerging resistance mechanisms guide next-generation therapeutics. Regulatory submissions justify receptor selection. Clinical validation confirms predicted therapeutic benefit.